REG - ReNeuron Group plc - Directorate Change

ReNeuronAnnouncement

01/08/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220801:nRSA3339Ua&default-theme=true

RNS Number : 3339U  ReNeuron Group plc  01 August 2022

 

ReNeuron Group plc

("ReNeuron" or the "Company" or the "Group")

 

Directorate Change

Catherine Isted appointed as Chief Executive Officer

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived
exosome technologies, announces the appointment of Catherine Isted, ACMA, as
Chief Executive Officer ("CEO"), effective 1 September 2022.

 

Ms. Isted joined the ReNeuron Board as Chief Financial Officer in October
2021. Following the departure of the former CEO in February this year, Ms.
Isted has worked closely with the Executive Management team, led by Iain Ross,
to refocus the business around the Group's differentiated exosomes delivery
platform.

 

Ms. Isted is an experienced strategic finance professional and chartered
management accountant with c.25 years' experience across the Healthcare
industry. This includes 12 years at partner level in two leading Healthcare
banking teams undertaking multiple Initial Public Offerings and follow-on
fundraisings. Within the Healthcare industry, prior to joining ReNeuron, Ms.
Isted has also held various in-house financial and strategic roles spanning
Corporate Development, Investor Relations and Financial Planning and Analysis.

 

Ms. Isted joined ReNeuron from Oxford Biomedica plc, a global leading cell and
gene therapy company, where she was instrumental in raising in excess of £110
million and supporting potential board level strategic opportunities. She has
also held senior research analyst and equity sales positions in the Healthcare
teams at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt. Ms. Isted holds a 1st
Class chemistry degree along with experience as a bench scientist, before
moving into finance and training as an accountant at Merck.

 

Iain Ross, Chairman, commented: "Over the last six months and under my
leadership, Catherine has worked with the executive team to refine the
strategic and operational focus of the Company. She has shown herself to be an
excellent candidate for the role and consequently, against external
competition, the Board has taken the decision to appoint Catherine as the new
CEO. I will revert to being non-executive Chairman after a period during which
I support the transition. We intend to announce further organisational changes
in due course."

 

Catherine Isted, incoming Chief Executive Officer, commented: "I feel
honoured and grateful for the confidence that Iain and the Board have put in
me to lead ReNeuron as we look to build a truly world class drug delivery
platform for the next generation of targeted medicines. ReNeuron has not only
great science but also great people and together that is a powerful
combination. I look forward to, and remain committed to, continuing to work
tirelessly to realise the full potential of ReNeuron for the benefit of all of
the Company's stakeholders."

 

ENDS

 

The person responsible for arranging for the release of this announcement on
behalf of the Company is Iain Ross, Chairman.

 

 

Contacts:

 

 ReNeuron Group plc                                www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                               Via Walbrook PR
 John Hawkins, Company Secretary

 Liberum Capital Limited (NOMAD and Joint Broker)  +44 (0)20 3100 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)            +44 (0)20 3328 5656
 James Reeve / George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)          +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus / Alice Woodings                     +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Group has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Group has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABLGDRCBDDGDC